Randomized Trial Comparing Dose Reduction and Growth Factor Supplementation for Management of Hematological Side Effects in HIV/HCV Patients Receiving Pegylated-Interferon and Ribavirin

類似資料

• Early Ribavirin Pharmacokinetics, HCV RNA and Alanine Aminotransferase Kinetics in HIV/HCV Co-infected Patients During Treatment with Pegylated Interferon and Ribavirin
  著者:: Dahari, Harel, 等
  出版事項: (2007)
• Intrahepatic and Peripheral CXCL10 Expression in Hepatitis C Virus–Infected Patients Treated With Telaprevir, Pegylated Interferon, and Ribavirin
  著者:: Zeremski, Marija, 等
  出版事項: (2015)
• Persistence of hepatitis C virus during and after otherwise clinically successful treatment of chronic hepatitis C with standard pegylated interferon α-2b and ribavirin therapy.
  著者:: Annie Y Chen, 等
  出版事項: (2013-01-01)
• Persistence of Hepatitis C Virus during and after Otherwise Clinically Successful Treatment of Chronic Hepatitis C with Standard Pegylated Interferon α-2b and Ribavirin Therapy
  著者:: Chen, Annie Y., 等
  出版事項: (2013)
• Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
  著者:: Hartl, Janine, 等
  出版事項: (2012)